Oxurion NV (XBRU:OXUR) Treasury Stock : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Oxurion NV's treasury stock for the quarter that ended in Dec. 2023 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Oxurion NV Treasury Stock Historical Data

The historical data trend for Oxurion NV's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Treasury Stock Chart

Oxurion NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Oxurion NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Oxurion NV Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Oxurion NV (XBRU:OXUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

TG4:Germany

Address

Gaston Geenslaan 1, Leuven, BEL, B-3001

Website

https://www.oxurion.com

Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines